LIZ: WELCOME BACK. INVESTORS PULLING THE PLUG ON TESLA TODAY, DOWN ABOUT 2.5% AT THE MOMENT. THIS DROP COMES AFTER THREE BROKERAGES CUT ESTIMATES FOR FIRST QUARTER DELIVERIES. RBC CAPITAL HIT THE TAPE FIRST THIS MORNING, SLASHING ESTIMATES FOR TESLA FIRST QUARTER DELIVERIES FROM 500,000 TO 446,000. WORKS OUT TO ABOUT A 10.7% CUT. THE EV MAKER'S STOCK IS DOWN 28% SO FAR THIS YEAR. LET'S CALL IT 29 RIGHT NOW. WORST PERFORMER ON THE S&P, AND IT IS COMPETING WITH SIR IS YOUS XM IN A RACE TO THE BOTTOM TO HAVE NASDAQ 100. HIS LEADERSHIP, AT LEAST FOR SOME IS, HAS COME INTO WITH QUESTION. SOME HAVE TIED THAT POOR STOCK PERFORMANCE AT TESLA TO HIS ADMITTED USE OF THE PRESCRIPTION DRUG KETAMINE P. FORMER CNN HOST DON LEMON, WHO WAS GRANTED AN INTERVIEW WITH MUSK ON LEMON'S UPCOMING, AND SHOW, BROUGHT UP THE ISSUE. >> YEAH. DO YOU EVER WORRY THAT THIS MAY GET IN THE WAY OF YOUR GOVERNMENT CONTRACTS AND CLEARANCES ALSO? AND WALL STREET AS WELL? >> WELL, FROM THE STANDPOINT OF WALL STREET, WHAT MATTERS IS EXECUTION. YOU KNOW? ARE YOU HOLDING VALUE FOR IF INVESTORSFUL TESLA IS WORTH ABOUT AS MUCH OF THE REST OF THE CAR INDUSTRY COMBINED FROM NOTHING. SO, YOU KNOW, THAT'S PRETTY GOOD. AS A I MENTIONED, WE HAVE THE BEST SELLING CAR ON % LAST YEAR. SO IS FROM AN INVESTOR STANDPOINT, IF THERE IS SOMETHING I'M TAKING, I SHOULD E KEEP TAKING IT. LIZ: LEMON WAS FIRED FROM X RIGHT AFTER THAT INTERVIEW. IS THERE NOW A RACE'SES TO CREATE MORE KETAMINE ON THE BEHALF OF BIG PHARMACEUTICALS? SHOULD INVESTORS BE CONCERNED AT LEAST ON THE TESLA SIDE? JOINING US NOW IS THE AUTO ANALYST WHO DOWNGRADED THE DELIVERIES NUMBERS, TOM RYAN, AND NYU LANGONE PROFESSOR OF MED SEVEN AND FOX BUSINESS CONTRIBUTOR -- MEDICINE AND FOX NEWS CONTRIBUTOR DR. MARC SIEGELING. DR. SIEGEL, LET'S BEGIN THIS BASELINE FACT, KETAMINE IS LEGAL. IT'S OFTEN A USED FOR EVERYTHING FROM DEPRESSION TO AN THESOLOGY, CORRECT? WHAT WAS ITS ORIGINAL USE, AND WHAT HAS THAT TRANSLATED AND MORPHED INTO NOW? IF. >> IT'S A PSYCHEDELIC, LIZ. IT AFFECTS THE BRAIN AND THE GATHER RECEPTORS, CAUSES A DISSOCIATION, HAPPINESS. IT'S TECHNICALLY A PSYCHEDELIC. IT WAS AROUND FOR 50 YEARS FIRST AS A HORSE TRACK TRANQUILIZER. THEY A FOUND A USE FOR IT IN ANESTHESIA A BECAUSE IT CAN PUT PEOPLE TO SLEEP WITHOUT AFFECTING THEIR BREATHING MUCH, BUT IT DOES INCREASE BLOOD PRESSURE, IT DOES AFFECT THE HEART AND HAS A LOT OF SHORT-TERM SIDE EFFECTS. FOR RECENTLY IT'S BEEN USED FOR DEPRESSION TO BREAK THE DEEP CYCLE OF DEPRESSION BECAUSE OF THOSE RECEPTORS I TALK ABOUT IN THE BRAIN. SO VERY, VERY, VERY ASTUTE AND WELL-TRAINED PSYCHIATRISTS CAN USE IT INTRAVENOUSLY TO BREAK THE CYCLE OF DEPRESSION KIND OF LIKE SHOCK THERAPY. STUDIES HAVE SHOWN THAT THAT WORKS. BUT AS USUAL, IT GETS -- THE GENIE GETS OUT OF THE BOTTLE, AND IT STARTS BEING USED RECREATIONALLY EVERYWHERE. OVER A MILLION PEOPLE USING THIS AT A VARIOUS DOSES WITHOUT ANY SUPERVISION CAN CAUSE NAUSEA, VOMITING, IT CAN AFFECT THE HEART AND P OF COURSE, THE PSYCHEDELIC IMPACT OF IT, YOU COULD BE DRIVING A CAR, YOU COULD GET E INTO A CAR ACCIDENT. WE'RE SEEING MORE AND MORE OF THAT. IT COULD BE COME WINED WITH OTHER -- COMBINED WITH OTHER MEDICATIONS OR ILLICIT DISCUSSION LIKE COKIN OR SPEED, AND YOU -- COCAINE OR SPEED AND YOU END UP WITH A RISKY SITUATION. NOBODY IF MONITORING IT. LIZ: OF COURSE, BEING USED WITH A PHYSICIAN'S SUPERVISION. BUT AT THIS POINT, YOU KNOW, DR- ELON MUSK HAS SOMEHOW BEEN ATTACKED FOR USING THIS. OTHERS LOOK AT IT SAW AND I CONCERN AND SAY, WAIT A MINUTE, HE HAS AN ADMITTED ISSUE WITH DEPRESSION. IT HAS BEEN PRESCRIBED FOR HIM, THIS IS A LEGAL ARE SUBSTANCE. SHOULD WE BE HANGING HIM OUT TO DRY FOR THIS? >> NO. THAT'S THE OTHER SIDE OF IT, NO, BECAUSE OF WHAT I SAID. I THINK IT IS VERY USEFUL FOR DEPRESSION, AND IF IT'S PRESCRIBED AND MONITORED BY A PHYSICIAN, I THINK IT'S A GREAT TREATMENT CHOICE. I DON'T KNOW ABOUT FOR HIM. I THINK THERE'S NOBODY MORE SUCCESSFUL IN THE WORLD RIGHT NOW THAN ELON MUSK IN MANY DIFFERENT WAYS INCLUDING NEURALINK WHICH I'M EXTREMELY INTERESTED IN, BY THE WAY. I HAVE A PROBLEM WITH THE ILLICIT USE ON THE STREET THAT CAN BE MIXED WITH OTHER ARE DRUGS, USED FOR OVERDOSES AND FILLING EMERGENCY ROOMS. HE SHOULDN'T BE ATTACKED FOR THIS AT ALL. LIZ: TOM, LET'S BRING IN THE INVESTOR PER SPECT EVERY. YOU AT RBC, I'M GOING TO DOUBT, HAVE HAD DISCUSSIONS WITH YOUR TEAM BECAUSE IT'S BEEN FRONT PAGE IN THE "WALL STREET JOURNAL," THERE HAVE BEEN MEMBERS OF THE BOARD WHO HAVE HOPED THAT HE COULD BE WEANED OFF OF THIS SOMEHOW. THEY'VE SEEN ERRATIC BEHAVIOR. BUT HOW BIG A DEAL IS THIS THE AS IT PLAYS INTO HOW YOU LOOK AT THE STOCK? >> YEAH, CERTAINLY IT'S THE NOT SOMETHING ACTUALLY THE THAT INVESTORS THAT WE HAVE SPOKEN TO HAVE REALLY FOCUSED ON. HONESTLY, WHEN PEOPLE LOOK AT THE STOCK, THEY TRY TO UNDERSTAND THE CORE FUNDAMENTALS OF THE BUSINESS. THERE'S OBVIOUSLY THE AUTO BUSINESS. THERE'S ALSO OTHER BUSINESSES, RIGHT? THERE'S ENERGY STORAGE, A AUTONOMY, FSD. SO REALLY INVESTORS HAVE BEEN MORE FOCUSED ON THE FUNDAMENTALS OF THE COMPANY AS POSED TO ANYTHING GOING ON PERSONALLY WITH THE CEO. LIZ: YOU KNOW, HE HAS BEEN DOING INTERVIEWS TALKING ABOUT THE DRUG USAGE A IN RECENT MONTHS. AND THIS IS WHAT THE STOCK STOCK HAS DONE OVER JUST THE PAST MONTH WHEN HE DID THAT INTERVIEW. I'M NOT SAYING THERE IS A CONNECTION, CERTAINLY, BUT INVESTORS CAN'T BE HAPPY ABOUT THIS. DO YOU THINK IT'S FAIR AT ALL TO SAY, WELL, MAYBE THIS IS A PIECE OF THE ISSUE? >> NO. THE STOCK'S MOVEMENT IN THE PAST MONTH HAS LARGELY BEEN DUE TO WHAT WE'RE ABOUT TO HAVE NEXT WEEK WHICH IS THE DELIVERY NUMBER FOR Q1 WHICH IS PROBABLY GOING TO BE THE A CHALLENGE BECAUSE OF A NUMBER OF THINGS HAPPENING. THE RED SEA CRISIS IMPACTED EUROPEAN IF PRODUCTION IN FEBRUARY, YOU HAD A PULL FORWARD OF DEMAND INTO Q4 BECAUSE OF THE IR.A. EXPIRING AND ONE OF THE KEY MODELS. YOU KNOW, THE MODEL 3 AND THE MODEL Y ARE KIND OF SATURATED A LITTLE BIT. THE NEW CAR THAT'S GOING TO COME OUT IN 2025, IT'S GOING TO TAKE SOME TIME. SO WE'RE IN A LULL BETWEEN TWO GROWTH PERIODS, SO WE'RE JUST, UNFORTUNATELY, IT'S JUST A FUNCTION OF NEAR TERM CONCERNS THAT THEY'RE GOING TO HAVE TO CUT PICING, THESE SORTS OFFER ISSUES -- OF ISSUES. THAT'S WHERE THE INVESTOR FOCUS IS. LIZ: MARC I WANT TO THE FINISHING WITH THIS, THE PSYCHEDELIC DRUG MARKET IS FORECAST TO REACH $6.4 BILLION BY 2023 -- 2034, YOU'VE GOT NAMES LIKE JOHNSON & JOHNSON AND PFIZER IN THE KETAMINE BUSINESS, MILEN PHARMACEUTICALSING OTHER NAMES HERE. EVERYBODY'S TALKING ABOUT OBESITY DRUGS, BUT COULD PSYCHEDELIC DRUGS REALLY BECOME A MUCH BIGGER OFFERING? >> THAT'S HUGE. IT'S HUGE. AND THE ONE THING THAT HASN'T BEEN REALLY HOOK ARED AT HERE WHICH I HINTED AT IS WHAT'S THE DOSE, YOU KNOW, WE TALKED ABOUT ELON MUSK, IS IT THE CORRECT DOSE, WHO'S MONITORING IT, AND MOST IMPORTANT OFLY OF ALL, COULD YOU YET THE SAME IMPACT WITH A DRUG THAT DIDN'T CAUSE THE PSYCHEDELIC EFFECT? IF WE'RE TALKING THERAPEUTICS HERE AND MEDICAL EFFECTS, WE WANT SOMETHING THAT HAS THE MEDICAL EFFECT WITHOUT SOMETHING THAT CAUSES AN OUT OF BODY EXPERIENCE THAT CAN INTERFERE WITH FUNCTION. LIZ: DR. MARC SIEGEL, TOM, W
